메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Antengene Presents Latest ATG-022 Clinical Data at ESMO 2025 Demonstrating Efficacy Across All CLDN18.2 Expression Levels and Exceptional Tolerability

SHANGHAI and HONG KONG, Oct. 20, 2025 -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematologic malignancies and solid tumors, today announced that the latest results from the ongoing Phase I/II CLINCH study of ATG-022 (CLDN18.2 antibody-drug conjugate [ADC]), were presented in a Poster Presentation at the European Society for Medical Oncology Congress 2025 (ESMO 2025) in Berlin, Germany.&nbs
- 김갑성 기자
- 2025-10-20 09:00
CARsgen Presents Preliminary Results on Satri-cel for Adjuvant Therapy of Pancreatic Cancer at ESMO Congress 2025

SHANGHAI, Oct. 20, 2025 -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the research results of the Phase Ib registrational clinical trial of satricabtagene autoleucel ("satri-cel", CT041) (an autologous CAR T-cell product candidate against protein Claudin18.2) for pancreatic cancer (PC) adjuvant therapy in China (CT041-ST-05, NCT05911217) has been presented in poster session at European Society for Medical Oncology (ESMO) Congress 2025. The poster was titled "Adjuvant Therap
- 김갑성 기자
- 2025-10-20 08:15
Ascletis Completes Enrollment in U.S. Phase IIa Study for Its Once-Monthly Subcutaneous Depot Treatment Formulation of Small Molecule GLP-1R Agonist ASC30 for Obesity

- The 12-week U.S. Phase IIa study is evaluating the efficacy, safety and tolerability of the once-monthly subcutaneous (SQ) depot formulation (treatment formulation) of small molecule GLP-1 receptor (GLP-1R) agonist ASC30 in 65 participants with obesity or overweight. - The ultra-long-acting SQ depot treatment formulation of small molecule ASC30 demonstrated a 46-day observed half-life in participants with obesity in the Phase Ib study, supporting once-monthly administration. - Topline data from the 12-week Phase IIa study of ASC30 once-monthly SQ depo
- 김갑성 기자
- 2025-10-20 08:10
ESMO 2025: CStone Discloses Phase I Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody)

SUZHOU, China, Oct. 20, 2025 -- CStone Pharmaceuticals ("CStone," HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, autoimmune/inflammation, and other key disease areas, today announced the first disclosure of preliminary Phase I data for CS2009 (a PD-1/VEGF/CTLA-4 trispecific antibody) and the Phase Ib study design for CS5001 (a ROR1-targeted Antibody-Drug Conjugate [ADC]) at the 2025 European Society for Medical Oncology (ESMO) Annual Congress. Key Highlights of CS2009 Poster Presentation:
- 김갑성 기자
- 2025-10-20 08:10
Clover Appoints Nicholas Jackson, Ph.D., as President of Global R&D and Alliances

SHANGHAI, Oct. 20, 2025 -- Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world, today announced the appointment of Nicholas Jackson, Ph.D., as President of Global R&D and Alliances. Dr. Jackson will work closely with the Company's CEO, Joshua Liang, to accelerate the development of Clover's RSV+hMPV±PIV3 combination vaccine candidates and lead potential alliances with global collaborators. "We are excited to welcom
- 김갑성 기자
- 2025-10-20 07:00
Significant OS Benefit with Cadonilimab in First-Line Advanced Gastric Cancer: Final Analysis of COMPASSION-15 Presented at ESMO 2025

HONG KONG, Oct. 19, 2025 -- On October 19, 2025, Akeso (9926.HK) announced the final analysis results from the COMPASSION-15/AK104-302 study at the 2025 European Society of Medical Oncology Congress (ESMO 2025) . COMPASSION-15 is a Phase III clinical trial evaluating cadonilimab, Akeso's first-in-class PD-1/CTLA-4 bispecific antibody, in combination with oxaliplatin and capecitabine as first-line treatment for unresectable, locally advanced, recurrent, or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. Professor Shen Lin, principal investigator from Peking University
- 김갑성 기자
- 2025-10-19 23:42
HARMONi-6 Data: mPFS 11.14 Months (HR=0.6, P<0.0001) Simultaneously Released at ESMO and in The Lancet

[ 메디채널 김갑성 기자 ] Ivonescimab plus chemotherapy demonstrated a median PFS of 11.14 months, PFS HR=0.60, P < 0.0001. The absolute difference in median PFS between the two groups was 4.24 months (ΔPFS = 4.24 months), indicating significantly prolonged progression-free survival with ivonescimab combination therapy. Significant benefits were consistently observed with ivonescimab plus chemotherapy versus tislelizumab combination irrespective of PD-L1 expression. Ivonescimab combination therapy showed significant benefit over tislelizumab regimen in patients with or without liver metastase
- 김갑성 기자
- 2025-10-19 23:37
United Imaging Marks Five Years Since the Opening of its Global Showroom In North America with a Record Number of U.S. Customer Visits

[ 메디채널 김갑성 기자 ] The company launched American R&D in 2013 and American commercial operations in 2018; in 2020 it opened a 100,000 square foot production and training center in Houston, and just tripled its local footprint to support strong growth. HOUSTON, Oct. 19, 2025 -- United Imaging, a global manufacturer of modern medical imaging technology, saw a record number of visits to its North American hub from U.S. healthcare providers in one week in October, and an overall spike in 2025. The nearly 100,000 square foot facility first opened its doors in Houston in 2020, and
- 김갑성 기자
- 2025-10-19 22:00
Multitude Therapeutics Announces Encouraging Interim Phase I/II Results from Ongoing First-in-Human Study Evaluating its MUC18-directed Antibody-Drug-Conjugate, AMT-253, in Melanoma and Other Advanced Solid Tumors at the 2025 ESMO Annual Meeting

[ 메디채널 김갑성 기자 ] AMT-253 is a potential first-in-class MUC18-directed ADC with a proprietary linker-payload design AMT-253 demonstrated a manageable safety profile, consistent with other TOP1-inhibitor based ADCs Promising antitumor activity was observed in heavily pretreated patients with melanoma and gynecologic cancers without MUC18 preselection SHANGHAI, Oct. 19, 2025 -- Multitude Therapeutics, Inc., a clinical stage biopharmaceutical company focused on the development of ADC drugs, today announced interim results from its ongoing Phase I/II open-label, multicente
- 김갑성 기자
- 2025-10-19 15:00
Case Report | Preliminary Clinical Data of CARsgen's Allogeneic BCMA CAR-T Product CT0596 for the Treatment of Primary Plasma Cell Leukemia

SHANGHAI, Oct. 19, 2025 -- Primary plasma cell leukemia (pPCL) is a rare and highly aggressive plasma cell malignancy, often associated with complex genetic abnormalities. There is currently no standard treatment regimens, and conventional therapies for multiple myeloma are typically used. While targeted agents and autologous hematopoietic stem cell transplantation can slightly extend the overall survival of pPCL patients to 1.5–3 years, relapsed/refractory pPCL after multiple lines of therapy presents a significant clinical challenge due to the extremely limited treatment options and
- 김갑성 기자
- 2025-10-19 14:00

이전

21 22 23 24 25 26 27 28 29 30

많이 본 기사

최근기사

2025-11-04_TUE

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 11월 04일 14시 40분